Newsfeed

New PAH Research Highlights Importance of Exercise
Exercise and fitness are two health factors that invariably affect prognoses for most chronic, progressive diseases. Given the stress and immobility that come as a result of illness, maintaining fitness to the best of the patient’s ability is generally a best practice for maximizing quality of life and lifespan. However, new PAH research suggests that patients’ muscles are affected by the disease at the cellular level, and that any measure of exe…
Freeze-dried plants may treat pulmonary hypertension
A drug grown in plant leaves and then freeze dried and enclosed in capsules might offer a much-needed treatment for pulmonary hypertension, a disease for which few therapy options exist. When rats with established pulmonary hypertension were treated with plant-delivered medication for two weeks, their pulmonary pressure was reduced by 20 percent. After four weeks, pulmonary pressure was reduced by 32 percent. RELATED ARTICLES ON FUTURITY …
Quebec breathes new hope into lives of those affected by pulmonary arterial hypertension
Patients elsewhere in Canada hope for swift access to new treatment option now funded in Quebec VANCOUVER, Oct. 8, 2014 /CNW/ - The Pulmonary Hypertension Association of Canada (PHA Canada) was pleased to learn that a new treatment option for pulmonary arterial hypertension (PAH) is now being publicly funded in the province of Quebec. On October 1, the Institut national d'excellence en santé et services sociaux (INESSS) recommended that the dr…
Noninvasive diagnosis ‘reliable’ for pulmonary hypertension diagnosis
medwireNews: Doppler echocardiography has good accuracy relative to right heart catheterisation for detecting pulmonary hypertension, shows a large study. The study involved 1695 patients at a single cardiac care centre who underwent Doppler echocardiography no more than 5 days before or after right heart catheterisation. Researcher Sebastian Greiner (University of Heidelberg, Germany) and team say that their study is considerably larger th…
Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients
Chronic thromboembolic pulmonary hypertension (CTEPH) is associated with chronic inflammation but the pathological mechanisms are largely unknown. Our study aimed to simultaneously profile a broad range of cytokines in the supernatant of pulmonary endarterectomy (PEA) surgical material, as well as prospectively in patients with CTEPH to investigate whether circulating cytokines are associated with haemodynamic and physical characteristics of CTEP…
New Targets For PAH Treatments Identified By Researchers
A new study published in September’s issue of the American Journal of Respiratory and Critical Care Medicine, entitled, “The Sphingosine Kinase 1 / Sphingosine-1-Phosphate Pathway in Pulmonary Arterial Hypertension” reports the discovery of two novel therapeutic targets to treat pulmonary arterial hypertension. Pulmonary arterial hypertension (PAH) is a result of elevated blood pressure in the arteries that supply the lungs, causing their walls …
Sarcoidosis-Associated Pulmonary Hypertension Highlighted By Recent Study
While a major population of pulmonary hypertension patients are diagnosed with idiopathic or arterial pulmonary hypertension, a population of patients with pulmonary hypertension patients due to sarcoidosis is no less affected by the condition. Estimates from a paper published in Seminars in Respiratory and Critical Care Medicine state that approximately 6-20% of sarcoidosis patients will develop pulmonary hypertension and see an increased risk o…
Bayer’s Adempas For CTEPH, PAH Confirmed Safe & Effective in Long-Term Studies
Findings collected during more than two years confirming the safety and efficacy of Bayer’s Adempas® (riociguat) in treating either inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), and patients with pulmonary arterial hypertension (PAH) were recently presented at the European Respiratory Society (ERS) Congress. Riociguat is the first member of a new class of soluble guanylate cyclase (sGC) stimulators tha…
Researchers find new targets for treating pulmonary hypertension
Two new potential therapeutic targets for the treatment of pulmonary arterial hypertension, a deadly disease marked by high blood pressure in the lungs, have been identified by researchers at the University of Illinois at Chicago. Their findings are reported in the American Journal of Respiratory and Critical Care Medicine. Early symptoms of pulmonary arterial hypertension include shortness of breath and exercise intolerance. As the disease progr…
First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study
-- AMBITION Study of Ambrisentan/Tadalafil Combination Therapy Versus Monotherapy Achieves Primary Endpoint of Time to First Clinical Failure Event -- -- Data Presented at the ERS International Congress 2014 -- MUNICH--(BUSINESS WIRE)--Sep. 8, 2014-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalaf…
Recent News

Subscribe

Get the latest on PH treatments, community events and more when you subscribe to our newsletter

ImagineCan_Accreditation_Trustmark_ENGFR_WHT-FNL_white.png